NEOP Pain Therapeutics and Neoprobe Present Promising Pipelines
The Bedford Report Provides Stock Research on Pain Therapeutics & Neoprobe Corporation
Press Release Source: The Bedford Report On Thursday June 30, 2011, 8:16 am
NEW YORK, NY--(Marketwire - 06/30/11) - There is plenty of optimism surrounding the biotech sector as firmer pricing and new products have improved sales and earnings trends. Meanwhile, younger, more speculative firms continue to garner significant attention with potential blockbuster products working their way through the regulatory process. The Bedford Report examines the outlook for companies in the biotechnology industry and provides equity research on Pain Therapeutics, Inc. (NASDAQ:PTIE - News) and Neoprobe Corporation (NASDAQ:NEOP - News). Access to the full company reports can be found at:
www.bedfordreport.com/PTIE
www.bedfordreport.com/NEOP
The importance of maintaining a steady pipeline of drugs to market is having varied effects on the biotechnology industry. Larger firms are leaning on acquisitions to quickly expand their product lines while smaller ones are opting for increased spending on research and development. This creates two potential avenues of profit for speculative biotech investors: a greater chance of a blockbuster drug or being acquired by a larger firm eager to boost its pipeline.
The Bedford Report releases investment research on the Biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.
Market Data 
Markets 
AI
